Navigation Links
Infusion of stem cells and specially generated T-cells from same donor improves leukemia survival
Date:2/27/2013

, lead author on the study and a research associate in the Fred Hutch Immunology Program.

The findings support expanding efforts to target WT1 and provide insights into what is necessary to establish potent and persistent T-cell responses in patients, and such second generation studies have recently been initiated at Fred Hutch.

All of the patients, who were treated post-transplant at Seattle Cancer Care Alliance, Fred Hutch's site for patient care, received adoptively transferred infusions of billions of enhanced CD8 cytotoxic T-cell clones. They were considered at high risk of death because they had already relapsed and/or had a poor prognosis due to unfavorable characteristics of their leukemia.

Four of the 11 patients in the trial received infusions of T-cells that targeted WT1 and were generated in the presence of IL-21. One had detectable relapsed disease and entered complete remission shortly after the T-cells were infused. All four survived after T-cell therapy without relapse for more than 30 months without suffering graft-vs.-host-disease and required no additional anti-leukemic treatment, according to the study. GVHD is a major complication of stem cell transplantation.

Among the seven patients who received infused T-cells generated without the presence of IL-21, two showed direct evidence of anti-leukemic activity, including one patient with advanced progressive disease who had a temporary response.

Researchers undertook the clinical trial because relapse remains a leading cause of death after allogeneic hematopoietic cell transplantation for patients with high-risk leukemias. An obstacle to survival is that the beneficial graft-vs.-tumor effect of a transplant can be offset by concurrent GVHD. Interestingly, patients who develop GVHD have reduced relapse rates. This suggests that lymphocytes present in engrafted donor stem cells can cause a concurrent therapeutic graft-vs.-tumor effect. However, because donor stem cells are not sele
'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Energy Infusion Meets Skin Care: Introducing Dahryn Silver Gel™
2. Acutrack integrates with Infusionsoft ecommerce platform
3. CareFusion, Baxter and Hospira Lead the Infusion Therapy Market as Hospitalization in the U.S. Climbs Reports iData Research
4. New drug prevents spread of human prostate cancer cells
5. Tiny hitchhikers attack cancer cells
6. To prevent leukemias dreaded return, go for the stem cells
7. Scientists identify major source of cells defense against oxidative stress
8. Therapy exploits addiction of leukemia cells
9. IBN discovers human neural stem cells with tumor targeting ability
10. Leukaemia cells have a remembrance of things past
11. Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... New Haven, CT (PRWEB) July 29, 2014 ... head up its Client Services Operation. , Christina Upton, ... been named Director of Client Services responsible for managing ... , Client Services is at the center of all ... the most well-known brands in the world . The ...
(Date:7/29/2014)... 1WorldSync announces B. Braun Melsungen AG, ... utilize the Global Data Synchronization Network™ (GDSN®) standard ... product information with the U.S. Food and Drug ... global supply chain. Holger Clobes, Head of Global ... Braun serves customers in 61 countries, among others ...
(Date:7/29/2014)... Collierville, TN (PRWEB) July 29, 2014 ... to the reimbursement model of all hospitals. Studies show ... tsunami.[1] One simple, easy, low cost tool that ... organizational performance by 20 to 25%. , Their secret? ... to one anther at the end of an operational ...
(Date:7/29/2014)... Doheny HealthDay Reporter , MONDAY, ... risk of cardiovascular disease may be able to take hormone ... harming their hearts, according to a new study. Previous ... replacement therapy had harmful effects on the heart. But, many ... treatments, and much further past menopause. In this ...
(Date:7/29/2014)... San Francisco, California (PRWEB) July 29, 2014 ... to reach USD 9,542.3 million by 2020, growing at ... according to a new study by Grand View Research, ... acceptance of these devices by the geriatric population, along ... are some of the major drivers of this market. ...
Breaking Medicine News(10 mins):Health News:CRN International Names New Director to Lead Client Services Department 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Early Hormone Therapy May Be Safe for Women's Hearts 2Health News:Early Hormone Therapy May Be Safe for Women's Hearts 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 2Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 4Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 5Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 6
... Human Services reported that very little precautionary measures can be ... flu) // . The infection in humans is actually caused ... ,Hence to prevent the global pandemic it has issued various ... a global pandemic. The government says that as such ...
... Guarraci, an assistance professor of psychology at south-western university and ... has a greater effect on the sexual behaviour of female ... and is among the first to determine the effects of ... also probes into the relationship between caffeine and sex. ...
... press that all the medical expenditures of pregnant women will be ... ,This plan is introduced mainly to ensure proper ... six months this plan will add $5 million to the annual ... the amount of expenditure of the rural women by $18. The ...
... of lives ever year. The need the organ, kidney is on ... ,Of all the organ transplantations done, kidney transplantation accounts ... sudden fall in the number of people who come forward to ... of the patients to undergo kidney transplants has widened to more ...
... Science Museum in London has found a unique way to help ... people the much-needed dose of light // . ,The ... of dark winter days. ,Up to 500,000 people, a ... seasonal affective disorder. SAD is more common in the northern ...
... an 8% increase in its share, following approval of Vivagel ... of HIV. // The company even signed a $20 ... and Infectious Diseases, an integral part of the National Institute ... for the prevention of HIV infection. The FDA recognizes the ...
Cached Medicine News:Health News:Starpharma Develops New Gel (Vivagel) To Prevent HIV Transmission 2
(Date:7/29/2014)... , July 29, 2014 ... today announced that it has taken an exclusive worldwide ... FScan Ltd, a Durham University ... Pharma will pay an upfront fee, development and commercial ... Pharma has also taken an option for additional exclusive ...
(Date:7/28/2014)... Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH ), today announced ... June 30, 2014. Net loss for the ... to $8.3 million for the same period in 2013. The ... decrease in interest expense in the current period.  ... 2014 was $15.2 million, compared with net loss of $15.9 ...
(Date:7/28/2014)... YORK , July 28, 2014 Reportbuyer.com ... Global Bone Densitometers Market 2014-2018 ... A bone densitometry scan is a special type of ... a bone. It is used primarily to detect osteopenia ... low and the risk of fractures is high. The ...
Breaking Medicine Technology:Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 2Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 5Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 6Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 7Global Bone Densitometers Market 2014-2018 2Global Bone Densitometers Market 2014-2018 3Global Bone Densitometers Market 2014-2018 4Global Bone Densitometers Market 2014-2018 5
... MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm® ... Inc., a wholly-owned subsidiary of Reckitt Benckiser Group plc ... market adoption of Suboxone® (buprenorphine HCl/naloxone HCl dihydrate) sublingual ... announcement of full-year 2010 financial results. ...
... Feb. 22, 2011 Prasco Laboratories ... supply agreement with Shire US Manufacturing, Inc. for ... Prasco, LLC is prepared to market the authorized ... Shire,s request, immediately upon any entrance into the ...
Cached Medicine Technology:MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010 2MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010 3
The Advance revision knee system was designed to address the unpredictable nature of revision knee arthroplasty by providing a wide variety of implant and instrument options....
... CRA femoral component is intended for ... and varus/valgus ligament stability, yet require ... inadequate bone stock. The NexGen CRA ... PMMA precoat surface. This device is ...
... manufacturers focus attention on implant design, one ... Profix Total Knee System seeks to establish ... system and the tools to implant them. ... recognized for innovation in total knee instrumentation, ...
Cruciate retaining, posterior stabilized and constrained components....
Medicine Products: